Contents

for authors

Cart

quick search

Vol. 79 2 2012

Impact of preoperative therapy with 5-a-reductase inhibitors in the treatment of benign prostatic hyperplasia

Article options

Impact of preoperative therapy with 5-a-reductase inhibitors in the treatment of benign prostatic hyperplasia

Urologia 2012; 79(2): 149 - 151

Article Type: ORIGINAL ARTICLE

DOI:10.5301/RU.2012.9277

Authors

Giacomo De Stefano, Ferdinando Fusco, Davide Arcaniolo, Antonio Pistone, Marco Capece, Simone Sannino, Vincenzo Mirone

Abstract

Benign prostatic hyperplasia is considered a progressive disease intimately linked with aging.
The long-term use of combination therapy with a 5-alpha-reductase inhibitor, together with an alpha blocker in men with moderate-severe symptoms, reduces the risk of clinical progression and BPH-related surgery.
It is unclear what the impact is of preoperative therapy with 5-ARI in patients that undergo surgery.
The aim of our study was to evaluate the impact of preoperative therapy with 5-alpha-reductase inhibitors on: a) indication on the type of surgery; b) surgical and functional outcomes; c) surgical complications.
This is a prospective observational study. It will include all patients undergoing surgery by TURP or Open Prostatectomy in a period of 24 months.
We expect results that demonstrate significant and favorable influence of pretreatment with 5-alpha-reductase inhibitors on certain outcomes. Therefore, therapy with 5-ARI could be considered as neoadjuvant to surgery, whatever this is.

Article History

  • • Accepted on 5/3/2012
  • • Available online on 5/16/2012
  • • Published in print on 5/29/2012

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

Authors

This article is available as full text PDF.

No supplementary material is available for this article.